Medical Condition News

RSS

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.

2 Jul 2010

Sensor-augmented insulin-pump therapy effective for type 1 diabetes patients

Adding a continuous blood sugar level sensor to an insulin pump helps patients with type 1 diabetes achieve better blood sugar control compared to the common standard of care, multiple daily insulin injections, concludes a study published on-line today in the New England Journal of Medicine.

2 Jul 2010

Twelve type 2 diabetes susceptibility loci identified

An international team co-led by scientists from the University of Michigan have discovered 12 more regions on the genome with DNA variants that are associated with increased risk of type 2 diabetes, bringing the number to 38.

2 Jul 2010

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Chelsea Therapeutics International, Ltd. announced the completion and favorable outcome of an independent Data Monitoring Committee (DMC) review of the safety and efficacy data from approximately half the target enrollment in Chelsea's Phase II trial of droxidopa in fibromyalgia.

2 Jul 2010

Visually impaired people dose accurately with insulin pens: Study

Labels on the popular insulin pen used by people with diabetes warn against visually-impaired people using pens to measure out and administer their insulin dosage.

2 Jul 2010

ISHLT issues first international consensus formulation of standardized nomenclature for CAV

Cardiac allograft vasculopathy (CAV), the major limitation to long term survival after heart transplantation, occurs when blood vessels in a transplanted heart progressively narrow and lead to dysfunction of the heart muscle or sudden death. Ascertaining benefit from appropriate treatment for this condition has been hampered in part because of the lack of a standard nomenclature.

2 Jul 2010

QR Pharma to present clinical data from mechanism of action study in MCI patients at ICAD 2010

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced today that it has been accepted to present a poster on clinical data from its recent mechanism of action study in mild cognitive impaired (MCI) patients at the International Congress on Alzheimer's Disease (ICAD 2010).

2 Jul 2010

Karolinska researchers recommend new routine for protection against infection during PEG

Researchers at Karolinska Institutet recommends a new routine for protection against infection when percutaneous endoscopic gastrostomy (PEG), a tube for feeding directly through the abdominal wall, is surgically inserted in the stomach. The new routine is both simpler and cheaper than the one used today. The method, presented in the British Medical Journal, has been clinically tested on over 200 patients at the Karolinska University Hospital in Solna, Stockholm County, Sweden.

2 Jul 2010

Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS

Compugen Ltd. announced today that administration of CGEN-15001 in an animal model of multiple sclerosis (MS) has been shown to completely abolish spontaneous relapses. In addition, administration of this novel molecule prior to disease onset demonstrated a pronounced delay of disease onset and a significant decrease in disease symptoms.

2 Jul 2010

Aushon BioSystems introduces new Human multiplex biomarker panels

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, has launched new Human multiplex biomarker panels for the quantification of eight biomarkers related to drug-induced kidney damage, or nephrotoxicity.

2 Jul 2010

Plant extract effective against ulcerative colitis in mice

A South Dakota State University scientist's research shows an extract made from a food plant in the Brassica family was effective in alleviating signs of ulcerative colitis, an inflammatory bowel condition, in mice.

2 Jul 2010

HL patients with heart disease at increased risk of hospitalization for cardiac complications after treatment

Older patients with Hodgkin lymphoma (HL) and a history of heart disease face a high risk of hospitalization for cardiac complications after completing treatment, according to research published online today in Blood, the journal of the American Society of Hematology. HL is a form of cancer of arising in the lymph nodes, and approximately 8,500 people were diagnosed with the disease in 2009, according to the American Cancer Society.

2 Jul 2010

Cambridge Heart announces CMS reimbursement modification for MTWA test

Cambridge Heart, Inc., today announced that effective July 1, 2010, the Centers for Medicare and Medicaid Services (CMS) will allow full reimbursement for both a Microvolt T-Wave Alternans (MTWA) test and a stress test when both tests are performed during the same patient visit. The CMS update removes a previous restriction that substantially limited reimbursement when a patient underwent an MTWA test on the same day as the patient underwent a standard cardiac stress test, echocardiography stress test, nuclear cardiac stress test, or pulmonary stress test.

2 Jul 2010

Parkinson's Disease Foundation awards $1.2M for research programs

The Parkinson's Disease Foundation (PDF) is pleased to announce awards totaling $1.2 million for research projects designed to understand the cause(s) of and find a cure for Parkinson's disease (PD).

2 Jul 2010

Frozen blood samples shows promise to study mechanism of blood disorders

Cells from frozen human blood samples can be reprogrammed to an embryonic-stem-cell-like state, according to Whitehead Institute researchers. These cells can be multiplied and used to study the genetic and molecular mechanisms of blood disorders and other diseases.

2 Jul 2010

OTA reminds consumers to choose organic foods over synthetic dye foods

In response to a call from the Center for Science in the Public Interest (CSPI) to ban synthetic dyes to color foods, the Organic Trade Association (OTA) today reminded consumers that they can already avoid such dyes in the marketplace by choosing to purchase organic foods.

2 Jul 2010

Heart patients with transient kidney dysfunction have no serious complications

New research led by UC Health cardiologists shows that while short-term worsening kidney function is frequent among patients with heart failure, these patients also have better outcomes than those who have persistent kidney failure

2 Jul 2010

Elements Behavioral Health acquires The Ranch in Tennessee

Elements Behavioral Health, provider of residential treatment services for addiction and co-occurring disorders, announced this week the acquisition of The Ranch in Nunnelly, Tennessee. Elements is best known to the public as the owner of the internationally famous Promises Treatment Centers in Malibu and Los Angeles, where many Hollywood celebrities have been treated successfully for substance abuse.

2 Jul 2010

UCLA study highlights traffic-related asthma flares in urban areas

A new academic study led by UCLA scientists has found that even brief exposure to ultrafine pollution particles near a Los Angeles freeway is potent enough to boost the allergic inflammation that exacerbates asthma.

2 Jul 2010

Diabetics need more 'heat awareness'

Hot weather and diabetes can make for a potentially dangerous combination, according to a Mayo Clinic presentation at the 92nd Annual Meeting of the Endocrine Society in San Diego, California, June 19-22.

2 Jul 2010